Archives: Speakers

Kuldeep Neote, Ph.D. is Vice President External Innovation at Eli Lilly and Company and is responsible for integrating external innovation into Lilly Research Labs. He was Senior Director at J&J Innovation Center-Boston responsible for New Venture activities for the Janssen R&D in the East Coast. He has been responsible for several academic and biotech collaboration including two opportunities in Canada and also served as the interim Head of JLABS@Canada. Dr. Neote is trained as a Molecule Biologist with an extensive background in drug discovery. He has been focused in the area of Immunology, Inflammation and Oncology and has a passion for implementing cutting edge scientific discoveries into practical drug discovery programs. Throughout his career, he has looked at creative scientific and business development collaborative and partnering opportunities that have resulted in tangible clinical translation of new scientific discoveries working in conjunction with academic and biotech companies. Formerly, Dr. Neote was Research Advisor/Director in Global External R&D at Eli Lilly in Indianapolis, IN and responsible for search and evaluation of Oncology in-licensing opportunities. Prior to Eli Lilly, he was a Discovery Scientist in Pfizer Inc. in Groton, CT. Dr. Neote initiated the Chemokine Receptor Drug Discovery platform that lead to several clinical candidates, and also discovered novel chemokines. Earlier in his career, Dr. Neote cloned one of the first chemokine receptors during his post-doctoral studies in Genentech. Dr. Neote earned her BSc. in Microbial and Cellular Biology at the University of Calgary, Calgary, Canada, and a Ph.D. in Human and Molecule Genetics at the University of Toronto, Toronto, Canada, where he was a major contributor in the understanding of the molecular basis of lysosomal storage diseases, in particular Tay Sachs and Sandhoff’s disease.

Querida started in 2012 as Editor for North America and moved into the Editor in Chief role in 2014, where she oversees the New York and London newsrooms. She previously was the online managing editor at Genetic Engineering & Biotechnology News (GEN), where she wrote news stories daily and assigned and edited multiple analytical feature stories and blogs a week. She has moderated several industry panels, is a published science writer and has produced science news stories for ABC and NBC. Querida also worked on a documentary for the Discovery Channel. She has a Master’s in Science, Health and Environmental Reporting from NYU. Querida majored in Physics at Mumbai University, where she graduated with honors.

Kevin Anderson is a Clinical Operations Director.  He has worked in drug development throughout his career at a number of leading companies including Amgen, Biogen, Shire and for the last six years Alexion.  He is currently overseeing a portfolio of rare disease neurology programs and a multinational team of Clinical Project Leaders.  He received his MBA from Boston College and his BA in from Eastern University.

Katherine Arbour is the Executive Director, Global Clinical Data Management at Alexion Pharmaceuticals, which develops medicines for patients with rare diseases. Prior to joining Alexion, Arbour was the Executive Director (Head) of Clinical Data Management at Moderna Therapeutics, a company that develops synthetic mRNA platform technology for use in vaccines, rare diseases, and personalized cancer treatments.

Prior to joining Moderna Therapeutics, Arbour was Senior Director, Clinical Data Management at ARIAD Pharmaceuticals, an oncology company that developed small-molecule medicines to transform the lives of cancer patients. For more than nine years, she had developed the data collection initiatives for the global development of the leukemia medicine Iclusig® (ponatinib) and the non-small cell lung cancer breakthrough medicine, Alunbrig® (brigatinib).

Prior to joining ARIAD Pharmaceuticals, Arbour led a variety of projects and project teams in the area of data management at contract research organizations, which included the development of a variety of medicinal products and medical devices.

Arbour received her master of liberal arts in biotechnology from the Harvard Extension School in 2011. In the 2012 spring semester, she introduced the elements of clinical investigation course at the Extension School and had continued to teach clinical trial research until 2019. She also earned a master of arts in biopsychology from the University of British Columbia, Vancouver, Canada, and a bachelor of arts, magna cum laude, with a major in psychology and minor in biology from the State University of New York at Plattsburgh.

Tania Snioch is Director Healthcare at GS1 Global Office. Tania supports the global healthcare user community with the aim to enhance the level of global GS1 standards adoption to help improve patient safety and supply chain efficiency.  She is responsible for overall GS1 Healthcare operations, special projects and GS1 Member Organisation (MO) support.

Prior to starting at GS1 Global Office, Tania worked for, GS1 Australia where she and her team assisted the Australian Healthcare industry to implement the GS1 standards through a range of state, territory and federal initiatives. 

Tania has an Honors degree in Biomedical Science from Monash University in Melbourne.